Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,940 total articles
Melco is trading near the low end of its 52-week range after a tough multi-market cycle. Recent 2025 results showed group property EBITDA of $1.4 billion, $2.4 billion of liquidity and a $400 million debt paydown. With Macau momentum, operational awards, and manageable near-term maturities, MLCO is a swing trade to the long side on improving fundam…
SK hynix appears to have moved from commodity DRAM supplier toward a differentiated AI-memory play. The strategic push into higher-margin AI-optimized HBM and customer partnerships could re-rate the stock if execution follows through. This trade idea lays out an entry at $95.00, a conservative target of $145.00 and a stop at $78.00, with a primary …
Liberty Energy (LBRT) just posted an earnings surprise, directional guidance and is trading at reasonable multiples for a mid-cap energy-services group expanding into distributed power. Given a favorable news backdrop for oil and a cleaner fundamental profile, we upgrade our rating and lay out a trade plan: enter at $25.30, stop at $23.00, target $…
Aura Biosciences (AURA) is a clinical-stage oncology biote ch with a differentiated virus-like drug conjugate platform and an active Phase 2 program for belzupacap sarotalocan (bel-sar / AU-011). With market cap around $724M and enterprise value near $639M, the stock offers a tradeable setup: entry at $7.00, target $12.00, stop $5.80. Positive Phas…
Navan looks like a high-conviction tactical long today. Recent quarterly results showed a 50% jump in gross booking volume and management raised full-year revenue guidance after an earnings beat. Balance sheet liquidity and low leverage give the company runway to scale AI-enabled products that improve margins and payment revenue. That said, ongoing…
Workday is trading near $141 with a market cap of roughly $34.5B, but free cash flow of about $3.0B implies an FCF yield north of 8%. Recent product momentum - agentic AI ARR approaching $500M and 200% YoY growth - should accelerate margin and FCF expansion over the next several quarters. This trade idea takes a constructive, managed-risk long stan…
Hemab Therapeutics is a small-cap coagulation-focused biotech that, by management’s account, carries a healthy cash position and several upcoming clinical and regulatory catalysts. The risk-reward favors a directional long: buy a clear entry, protect with a tight stop, and scale into upside as readouts or partnership news arrive. This trade targets…
Greggs combines a simple, repeatable retail model with a strong brand and resilient margins. With near-term macro uncertainty priced into the stock and recent weakness compressing the valuation, we view the current levels as an attractive opportunity for a mid-term long trade. Our plan sets a clear entry, stop, and target and defines the catalysts …
Goldman Sachs reported a stronger-than-expected Q2 and the stock is trading near a new 52-week high. The beat highlights resilient trading and growing net interest income, and the market is rewarding banks as rate-sensitive earnings normalize. I present a clear swing trade: buy GS at market, target $1300 in ~45 trading days, stop at $1020. The trad…
Deckers (DECK) is a premium footwear and apparel house with durable margins, strong free cash flow and two global brands (UGG and HOKA) that can carry earnings even as growth moderates. The market has repriced future growth — that creates a swing trade opportunity to buy into quality at a reasonable multiple. Entry $106.62, stop $96.00, target $125…
Castor Maritime (CTRM) trades near $2.07 with a market cap of roughly $20M while recent quarterly profit and a major asset-manager acquisition point to a material valuation disconnect. This trade targets a mid-term rerating to $4.00 on recognition of assets and improved liquidity; stop at $1.75 to limit downside.
HUYA is positioned to monetize virtual personas with its AI VAM 1.0 rollout. At a $549M market cap and a sub-$3 stock price, the risk/return favors a long stance if adoption accelerates. This trade plan sets an entry at $2.35, stop at $1.95 and target at $4.50 with a long-term horizon to allow monetization and earnings re-rating.
Lundin Gold’s Fruta del Norte is a self-funding, high-quality gold operation with a market cap of roughly $13.3B, a trailing PE of ~14.2 and a 2.23% yield. The stock has pulled back to the mid-$50s and offers an attractive risk/reward if you buy a clear dip. Trade plan: enter $54.00, stop $48.00, target $80.00 over a long-term (180 trading days) ho…
Interactive Brokers is trading near $95.66 with strong traffic and account growth, >$16.7B free cash flow, low leverage and high margins. Technicals support continued strength above moving averages. We lay out an actionable long trade for a 180-trading-day horizon with entry, stop and target, plus catalysts and key risks.
Deep Fission is a small-cap reactor play with a $637M market cap, active short pressure, and clear upside to prior highs. This trade plan buys the stock at the current price to capture deployment news and momentum while limiting downside with a tight stop.
Firefly Aerospace has been punished after a recent launch failure. The market has sold first and asked questions later. For traders willing to accept above-average risk, a size-restricted long here offers asymmetric reward: a snap-back if upcoming milestones go clean and program execution is validated. This trade idea lays out entry, stop, targets,…
ServiceTitan's core field-service software remains well positioned to commercialize AI features. The company can expand ARR per customer through automation, scheduling optimization, and price-prescriptive tools. That upside is real, but near-term macro and spending cadence among trade customers creates a binary outcome. This trade idea targets asym…
Main Street Capital (MAIN) trades like a distressed credit story despite solid fundamentals: a diversified lower-middle-market portfolio, rising monthly dividend ($0.265/mo), manageable leverage (debt/equity ~0.82) and a cash-generative business model. The recent private-credit sell-off pushed valuation to attractive levels (P/E ~11.4, P/B ~1.58). …
Workday has been punished alongside other enterprise software names on fears that large language models will displace its core HCM and finance workflows. Fundamentals and cash generation argue otherwise. At $140.90 the stock offers an asymmetric risk/reward for a mid-term swing trade.
QXO fell after completing a transformative $17B acquisition of TopBuild. The market sold the news on dilution and leverage, but the combined company should generate roughly $18B in revenue and $2B in adjusted EBITDA with $300M of synergies by 2030. At $14.48, QXO trades at a modest tangible book multiple with negative EPS but positive free cash flo…
Amazon is repeating its AWS bet as it heads into the Q2 report cycle. With a $2.66T market cap, a P/E near 29x and EV/EBITDA around 17x, the stock offers a play on accelerating AI infrastructure demand. This trade sets a clear entry, stop and target with a mid-term (45 trading days) horizon to capture a re-rating if revenue and guidance tilt toward…
Xencor is a small-cap biotech ($1.11B market cap) that has been transitioning from partner-driven royalties to an increasingly in-house clinical portfolio built on its XmAb platform. With revenue momentum (Q2 2025 revenue up 82% to $43.6M), a recent financing haul and visible milestone receipts, the stock at $14.95 looks like a reasonable long trad…
Runway Growth Finance (RWAY) is a small-cap business development company that has grown assets through the SWK acquisition and pays a sizable quarterly distribution. Balance-sheet moves and a recent debt offering have spooked the market; the share price has collapsed toward the multi-week low and now trades below its 50-day average. The business fu…
SELLAS Life Sciences (SLS) is trading at $13.32 after a steady rebound from 2025 lows. The name combines an early-stage CDK9 inhibitor (SLS009) with an immunotherapy asset (galinpepimut-S) and has a runway of positive news flow and regulatory interest. With a market cap near $2.47B, unusually high short interest (~63M shares), and clear technical m…
Leonardo looks mispriced relative to its strategic position in European defense. With program-level visibility, steady cash conversion, and accelerating procurement across NATO members, the stock offers an attractive risk-reward for a long-term trade. Enter at $7.50, stop $6.00, target $10.00 over a 180-trading-day horizon.
